Skip to main content
. 2021 Oct 3;16(1):151–158. doi: 10.1111/irv.12912

TABLE 1.

Distribution of observed hospital cost, length of stay, and ICU admission stratified by predictors in adult patients with RSV‐associated hospitalizations

Predictors N = 601 Costs (2020 $) LOS (days) ICU admission
n, % Mean [CI95] Mean [CI95] %
Age (years)
Mean: 67 [CI95 65–68]
18–49 (reference) 85 (14%) $11,124 [$6522–$17,386] 10 [6–14] 22%
50–64 173 (29%) $7384 [$5743–$9534] 6 [5–7] 11%*
≥65 343 (57%) $8241 [$6957–$9758] 8 [7–9] 15%
Gender
Male (reference) 249 (41%) $8763 [$7003–$10,893] 7 [6–9] 16%
Female 352 (59%) $8148 [$6669–$9943] 8 [7–9] 14%
Comorbidities (reference: No)
Chronic lung Yes 296 (49%) $7672 [$6552–$8968] 7 [6–8] 17%
No 305 (51%) $9111 [$7157–$11,483] 8 [7–9] 13%
Cardiovascular Yes 337 (56%) $9707* [$7827–$11,896] 8 [7–9] 15%
No 264 (44%) $6738 [$5673–$7983] 7 [6–9] 14%
Immunosuppression Yes 174 (29%) $8359 [$6760–$10,222] 8 [6–9] 13%
No 427 (71%) $8420 [$6949–$10,169] 8 [7–8] 16%
Neurologic Yes 145 (29%) $6824* [$5025–$9429] 7 [6–8] 10%
No 456 (76%) $8904 [$7533–$10,506] 8 [7–9] 16%
Diabetes mellitus Yes 257 (43%) $7596 [$6386–$9068] 7 [7–8] 15%
No 344 (57%) $9006 [$7223–$11,137] 8 [7–9] 14%
Obesity Yes 179 (30%) $7810 [$5903–$10,630] 7 [6–8] 12%
No 422 (70%) $8653 [$7287–$10,199] 8 [7–9] 16%
Chronic kidney disease Yes 168 (28%) $9022 [$7036–$11,370] 8 [7–10] 15%
No 433 (72%) $8163 [$6799–$9825] 7 [6–8] 15%
Chronic liver disease Yes 42 (7%) $13,422 [$7129–$21,471] 9 [6–13] 16%
No 559 (93%) $8025 [$6913–$9340] 7 [7–8] 15%
Comorbid condition count
0 (reference) 33 (5%) $6501 [$3303–$11,620] 9 [4–16] 24%
1–3 470 (78%) $8359* [$7069–$9892] 8* [7–8] 15%
≥4 98 (16%) $9250* [$6459–$12,848] 7 [6–9] 12%
Living situation on admission
Independent (reference) 277 (46%) $8609 [$6761–$10,901] 7 [6–8] 15%
At home with assistance of friends, family, or aide 245 (41%) $7105 [$5661–$8970] 7 [6–8] 10%
Skilled nursing facility/assisted living 79 (13%) $11,706* [$8694–$15,199] 12* [9–15] 27%*
RSV season
2017–2018 (reference) 287 (48%) $9375 [$7557–$11,518] 8* [7–9] 16%
2018–2019 314 (52%) $7160 [$6182–$9286] 7 [6–8] 14%
Met SIRS criteria
Yes 265 (44%) $10,025* [$8205–$12,165] 8* [7–10] 21%*
No (reference) 336 (56%) $7123 [$5751–$8892] 7 [6–8] 10%
LOS (days)
Mean: 8 [CI95 7–8]
1–3 (reference) 158 (26%) $2815 [$2473–$3197] NA 4%
4–6 214 (36%) $4874* [$3948–$6406] NA 7%
7–10 127 (21%) $8367* [$6817–$11,033] NA 15%*
≥11 102 (17%) $24,485* [$19,945–$30,066] NA 47%*
Admitted to ICU
Yes 88 (15%) $20,577* [$15,909–$26,623] 16* [13–20] NA
No (reference) 513 (85%) $6313 [$5367–$7455] 6 [6–7] NA
ICU LOS (days)
Mean: 9 [CI95 7–11]
0 (reference) 515 (86%) $6319 [$5378–$7456] 6 [6–7] NA
1–2 16 (3%) $7010 [$4204–$11,008] 6 [4–9] NA
≥3 70 (12%) $24,024* [$18,537–$31,310] 18* [15–23] NA
Mechanical ventilation
Yes 62 (10%) $24,074* [$17,936–$32,209] 18* [14–23] NA
No (reference) 539 (90%) $6599 [$5662–$7694] 6 [6–7] NA
Ventilator‐days a
Mean: 11 days [CI95 8–14]
0 (reference) 523 (87%) $6421 [$5478–$7545] 6 [6–7] NA
1–7 30 (7%) $12,534* [$9568–$15,890] 10* [8–13] NA
≥8 31 (6%) $33,505* [$23,740–$47,157] 25* [19–33] NA
Antibiotic use
Yes 459 (76%) $8883* [$7594–$10,424] 8* [8–9] 18%*
No (reference) 142 (24%) $6852 [$4659–$9828] 5 [4–6] 4%
Died during hospitalization
Yes (reference) 27 (4%) $8108* [$6936–$9468] 12 [9–17] 63%
No 574 (96%) $14,669 [$9140–$21,350] 7* [7–8] 37%*

Abbreviations: CI, confidence interval; ICU, intensive care unit; LOS, length of stay; NA, not applicable; RSV, respiratory syncytial virus; SIRS, Systemic Inflammatory Response Syndrome.

a

Ventilator‐days were unavailable for one patient.

*

p < 0.05 when compared against reference.